Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bone graft shows promise in helping spine surgery patients heal

NCT ID NCT05972616

Disease control Sponsor: Induce Biologics USA Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well a bone graft material called Natural Matrix Protein (NMP™) works in 53 patients who had spinal fusion surgery for degenerative disc disease. The main goal was to see if the bones fused properly on CT scans and X-rays. Researchers also measured changes in disability using a patient questionnaire. The study is completed and provides early data on this product's performance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Natural Matrix Protein (NMP) - a human bone allograft used to promote spinal fusion
What this could lead to
If successful, this could confirm that NMP™ is a safe and effective option for helping bones fuse after spinal surgery, potentially improving surgical outcomes.
What could go wrong
This is a small, single-center review with no comparison group, so results may not apply to all patients. The study is completed but only evaluates short-term fusion and disability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

53 people

The number who actually took part.

Started

Aug 2023

Finished

Feb 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include up to 135 patients of the Spine Institute of Louisiana (SIL) who have been treated with Induce Biologics NMP™ during a lumbar interbody fusion. All subjects who meet all inclusion criteria and do not meet any exclusion criteria will be included in the study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have clinical or radiological evidence of degenerative disc disease of the lumbar spine. 2. Have been treated with Induce Biologics NMP™ during a lumbar spinal fusion procedure. 3. Be at least 18 years of age. 4. Have current contact information. 5. Be willing and able to provide written Informed Consent for the prospective part of study participation. 6. Be willing and able to undergo a CT-scan and X-rays. 7. Be willing and able to complete patient centered outcome questionnaires. Exclusion Criteria: 1. Currently imprisoned. 2. Currently experiencing major mental illness (psychosis, schizophrenia, major affective disorder) which in the opinion of the investigator may indicate that the symptoms are psychological rather than of physical origin. 3. X-rays or CT-scan are contraindicated. 4. Any previous lumbar fusion or arthroplasty surgery at the index level(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intervertebral disk degenerative disorder lumbar disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Degenerative disc disease

Contacts and locations

Locations

  • Spine Institute of Louisiana

    Shreveport, Louisiana, 71101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.